Analyst Maintains Buy on iX Biopharma, Sees Post-FY26 Transition Driving Strong FY27+ Rebound and Keeps DCF-Based S$1.00 Target PriceTip Ranks·Sep 1 at 01:15 PM42C+15.74%OEC-3.06%
OEC: Global carbon black leader with resilient earnings, strong cash flow, and high-growth outlookQuartr·Sep 1 at 07:09 AMOEC-3.06%
Orion S.A. (NYSE:OEC) Receives Consensus Recommendation of "Strong Sell" from BrokeragesMarket Beat·Aug 22 at 06:44 AMOEC-3.06%
Orion S.A. to Participate in Upcoming Investor Conferences | OEC Stock NewsStockTitan·Aug 19 at 12:15 PMOEC-3.06%
Orion (NYSE:OEC) Issues Earnings Results, Misses Expectations By $0.02 EPSMarket Beat·Aug 6 at 03:26 AMOEC-3.06%
Orion Q2 FY26 net income falls 80% to $1.8 million; net sales rise 7% to $500.9 millionPUBT·Aug 5 at 09:58 PMOEC-3.06%
OEC: Specialty segment strength and improved cash flow drove sequential EBITDA growth, despite YoY declinesQuartr·Aug 5 at 09:46 PMOEC-3.06%
Orion SA | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 500.9 MEarnings Watch·Aug 5 at 09:24 PMOEC-3.06%
OEC: Net sales rose 7% but net income fell 80% as oil-driven cost pressures hit marginsQuartr·Aug 5 at 09:23 PMOEC-3.06%
